You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MYC

Showing 1 - 25 of 301
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Recruiting
  • NSCLC
  • +6 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Dec 20, 2022

Metastatic Pancreatic Cancer Trial in Spain (OMO-103, Nab-Paclitaxel, Gemcitabine)

Recruiting
  • Metastatic Pancreatic Cancer
  • L´Hospitalet de Llobregat, Barcelona, Spain
  • +3 more
Sep 22, 2023

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

Not yet recruiting
  • DLBCL
  • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
  • Qingdao, Shandong, China
    the affiliated hospital of Qingdao University
Aug 18, 2022

Advanced Solid Tumors, NSCLC, Triple-negative Breast Cancer Trial in Barcelona, Madrid (OMO-103)

Active, not recruiting
  • Advanced Solid Tumors
  • +3 more
  • OMO-103
  • Barcelona, Spain
  • +2 more
Sep 27, 2022

Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +6 more
  • Cincinnati, Ohio
  • +4 more
Aug 3, 2022

Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • San Antonio, Texas
    Next Oncology
Aug 9, 2022

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
Feb 27, 2022

C-myc Biomarker Study for Diabetic Foot Ulcers

Recruiting
  • Diabetes
  • +3 more
    • San Francisco, California
    • +5 more
    Mar 9, 2022

    Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +4 more
    • DA-EPOCH-R followed by Nivolumab
    • Antwerpen, Belgium
    • +23 more
    Mar 23, 2022

    Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement

    Recruiting
    • Lymphoma
    • +4 more
    • Vysis LSI MYC Break Apart Rearrangement Probe Kit
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

    Not yet recruiting
    • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
    • +21 more
    • Biopsy
    • +8 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 7, 2023

    Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

    Not yet recruiting
    • Recurrent ALK Positive Large B-Cell Lymphoma
    • +28 more
    • Biospecimen Collection
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 17, 2022

    Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

    Not yet recruiting
    • Double-Expressor Lymphoma
    • +3 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Oct 27, 2022

    ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

    Active, not recruiting
    • ALK-Positive Large B-Cell Lymphoma
    • +34 more
    • Phoenix, Arizona
    • +32 more
    Jan 3, 2023

    Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma Trial in Worldwide (RO6870810, Venetoclax, Rituximab)

    Completed
    • Diffuse Large B-cell Lymphoma
    • High-Grade B-cell Lymphoma
    • Duarte, California
    • +8 more
    Jan 21, 2022

    Diffuse Large B-cell Lymphoma Trial in Beijing, Shanghai (R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
    • +2 more
    • Beijing, Beijing, China
    • +1 more
    Aug 8, 2021

    Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

    Active, not recruiting
    Has Results
    • Burkitt Lymphoma
    • +2 more
    • La Jolla, California
    • +29 more
    Nov 2, 2021

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

    Withdrawn
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +9 more
    • Autologous Hematopoietic Stem Cell Transplantation
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Ewing Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma Trial in United States (PRT2527)

    Recruiting
    • Ewing Sarcoma
    • +7 more
    • Denver, Colorado
    • +5 more
    Jun 9, 2022

    Lymphoma, Leukemia Trial in United States (CPI-613)

    Recruiting
    • Lymphoma
    • Leukemia
    • Duarte, California
    • +9 more
    Nov 28, 2022

    High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,

    Recruiting
    • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
    • +4 more
    • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
    • Jinan, Shandong, China
      Shandong Provincial Hospital
    Nov 18, 2021

    High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

    Recruiting
    • High Grade B-Cell Lymphoma, Not Otherwise Specified
    • +4 more
    • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
    • R-CHOP; R-DA-EPOCH; R-HD MTX
    • Jinan, Shandong, China
      Department of Hematology, Shandong Provincial Hospital
    Dec 7, 2021

    DLBCL Trial (R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide,hydroxyldaunorubicin,Vincristine,Prednisone)))

    Not yet recruiting
    • DLBCL
    • (no location specified)
    Apr 12, 2021